In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Intarcia Therapeutics Inc.

www.intarcia.com

Latest From Intarcia Therapeutics Inc.

Bookmark
  • News

Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals

By Michael Cipriano and Bridget Silverman

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals
Bookmark
  • Analysis

Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions

By Ian Haydock, Brian Yang, Anju Ghangurde, Jung Won Shin and Joseph Haas

The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.

Deals Commercial
Bookmark
  • Analysis

Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx

By Joseph Haas, Jo Shorthouse and Eleanor Malone

All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.

Deals Business Strategies
Bookmark
  • Analysis

Numab's Pipeline To Benefit From Intarcia Licensing Its ND016

By Sten Stovall

Privately held Swiss immunology and immuno-oncology specialist Numab Therapeutics has licenced its tri-specific antibody ND016 to Boston-based Intarcia Therapeutics, and will use the proceeds to advance its own drug pipeline, its co-founder tells Scrip.

Deals ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • BioMedicines Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intarcia Therapeutics Inc.
  • Senior Management
  • Kurt Graves, Chmn., Pres. & CEO
    James Ahlers, CFO
    Fred Fiedorek, MD, CMO, Global Head, Reg. Affairs
    Andrew Young, MD, PhD, CSO
  • Contact Info
  • Intarcia Therapeutics Inc.
    Phone: (617) 936-2500
    One Marina Park Dr., 13th Fl.
    Boston, MA 02210
    USA
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By